TY  - GEN
AU  - Manso,Luís
AU  - Palomo,Andrés García
AU  - Pérez Carrión,Ramón
AU  - Cassinello,Javier
AU  - Gallegos Sancho,Isabel
AU  - Chacón López-Muñiz,Ignacio
AU  - Olier,Clara
AU  - Fernández-Aramburo,Antonio
AU  - Llorca,Cristina
AU  - González,Xavier
AU  - Llorente,Rosa
AU  - Torregrosa,Dolores
AU  - Álvarez,Iñaki
AU  - Gálve,Elena
AU  - Bueno,Coralia
AU  - Garau,Isabel
AU  - García,María José
AU  - González-Santiago,Santiago
AU  - Ballesteros,Ana Isabel
AU  - Blanco,Esperanza
AU  - Galán,Antonio
AU  - González,Sonia
AU  - Perelló,Antonia
AU  - Cortés-Funes,Hernán
AU  - Grávalos,Cristina
TI  - Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study
SN  - 1791-7530
PY  - 2016///0331
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Bevacizumab
KW  - administration & dosage
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Cross-Sectional Studies
KW  - Female
KW  - Humans
KW  - Neoplasm Metastasis
KW  - Paclitaxel
KW  - Quality of Life
KW  - Receptor, ErbB-2
KW  - metabolism
KW  - Triple Negative Breast Neoplasms
N1  - Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
ER  -